IGF2BP2 and hepatocellular carcinoma: Autoimmune response to IGF2BP2 observed in hepatocellular carcinoma (HCC) and colorectal, ovarian, and breast cancer supports the potential of the autoantibody against IGF2BP2 as a biomarker in cancer screening, diagnosis, and prognosis [22–24].